Please login to the form below

Not currently logged in
Email:
Password:

Akari Therapeutics strengthens board

Hires Michael Grissinger and Dr Peter Feldschreiber

Mike GrissingerBiopharmaceutical company Akari Therapeutics has bolstered its board of directors with the addition of Michael Grissinger and Dr Peter Feldschreiber.

Grissinger (pictured right) has spent 22 years at Johnson & Johnson, holding positions of vice president and head of worldwide pharmaceutical licencing, as well as vice president and head of worldwide pharmaceutical corporate development and M&A.

His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and strategic planning to Akari.

Alongside Grissinger, Dr Peter Feldschreiber also joins the board bringing 20 years’ experience in the pharmaceutical industry.

He has held appointments as senior medical assessor and special litigation coordinator to the healthcare products regulatory agency.

Ray Prudo, executive chairman of Akari Therapeutics, said: “We are pleased to strengthen our board with two individuals that bring such a range and depth of healthcare industry experience.

“As Akari continues its mission to develop and commercialise treatments for orphan autoimmune and inflammatory disease, we look forward to benefitting from Michael’s expertise as a successful business and corporate development leader and Peter’s insight as a medical doctor with experience both in the pharmaceutical industry and the legal and regulatory aspects of healthcare.”

31st January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics